310 related articles for article (PubMed ID: 27593928)
21. LSD1: biologic roles and therapeutic targeting.
Maiques-Diaz A; Somervaille TC
Epigenomics; 2016 Aug; 8(8):1103-16. PubMed ID: 27479862
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
23. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
24. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
25. Current and potential epigenetic targets in multiple myeloma.
Pawlyn C; Kaiser MF; Davies FE; Morgan GJ
Epigenomics; 2014 Apr; 6(2):215-28. PubMed ID: 24811790
[TBL] [Abstract][Full Text] [Related]
26. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
[TBL] [Abstract][Full Text] [Related]
27. The future therapeutic potential of histone demethylases: A critical analysis.
Natoli G; Testa G; De Santa F
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
[TBL] [Abstract][Full Text] [Related]
28. [Advances in histone methyltransferases and histone demethylases].
Wang X; Zhu WG
Ai Zheng; 2008 Oct; 27(10):1018-25. PubMed ID: 18851779
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
31. Oncoepigenomics: making histone lysine methylation count.
Decarlo D; Hadden MK
Eur J Med Chem; 2012 Oct; 56():179-94. PubMed ID: 22975593
[TBL] [Abstract][Full Text] [Related]
32. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
Eglen RM; Reisine T
J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
[TBL] [Abstract][Full Text] [Related]
33. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Whitman SP; Hackanson B; Liyanarachchi S; Liu S; Rush LJ; Maharry K; Margeson D; Davuluri R; Wen J; Witte T; Yu L; Liu C; Bloomfield CD; Marcucci G; Plass C; Caligiuri MA
Blood; 2008 Sep; 112(5):2013-6. PubMed ID: 18566324
[TBL] [Abstract][Full Text] [Related]
34. Controllers of histone methylation-modifying enzymes in gastrointestinal cancers.
Li L; Song Q; Zhou J; Ji Q
Biomed Pharmacother; 2024 May; 174():116488. PubMed ID: 38520871
[TBL] [Abstract][Full Text] [Related]
35. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
[TBL] [Abstract][Full Text] [Related]
37. Emerging epigenetic targets and therapies in cancer medicine.
Popovic R; Licht JD
Cancer Discov; 2012 May; 2(5):405-13. PubMed ID: 22588878
[TBL] [Abstract][Full Text] [Related]
38. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
[TBL] [Abstract][Full Text] [Related]
39. Chromatin proteins and modifications as drug targets.
Helin K; Dhanak D
Nature; 2013 Oct; 502(7472):480-8. PubMed ID: 24153301
[TBL] [Abstract][Full Text] [Related]
40. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.
Koldobskiy MA; Abante J; Jenkinson G; Pujadas E; Tetens A; Zhao F; Tryggvadottir R; Idrizi A; Reinisch A; Majeti R; Goutsias J; Feinberg AP
Epigenetics; 2020 Aug; 15(8):841-858. PubMed ID: 32114880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
